Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 359

1.

PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.

Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK.

Mod Pathol. 2011 Mar;24(3):412-24. doi: 10.1038/modpathol.2010.176. Epub 2010 Oct 1.

2.

PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.

Long KB, Srivastava A, Hirsch MS, Hornick JL.

Am J Surg Pathol. 2010 May;34(5):723-9. doi: 10.1097/PAS.0b013e3181da0a20.

PMID:
20414099
3.
4.

Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.

Koo J, Mertens RB, Mirocha JM, Wang HL, Dhall D.

Mod Pathol. 2012 Jun;25(6):893-901. doi: 10.1038/modpathol.2012.34. Epub 2012 Mar 2.

5.

Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.

Lai JP, Mertens RB, Mirocha J, Koo J, Venturina M, Chung F, Mendez AB, Kahn M, Dhall D.

Endocr Pathol. 2015 Mar;26(1):54-62. doi: 10.1007/s12022-014-9346-3.

PMID:
25433656
6.

The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.

Koo J, Zhou X, Moschiano E, De Peralta-Venturina M, Mertens RB, Dhall D.

Endocr Pathol. 2013 Dec;24(4):184-90. doi: 10.1007/s12022-013-9264-9.

PMID:
24037217
7.

Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1.

Weissferdt A, Tang X, Wistuba II, Moran CA.

Mod Pathol. 2013 Dec;26(12):1554-60. doi: 10.1038/modpathol.2013.111. Epub 2013 Jun 21.

8.

Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors.

Lorenzo PI, Jimenez Moreno CM, Delgado I, Cobo-Vuilleumier N, Meier R, Gomez-Izquierdo L, Berney T, Garcia-Carbonero R, Rojas A, Gauthier BR.

Histochem Cell Biol. 2011 Nov;136(5):595-607. doi: 10.1007/s00418-011-0866-3. Epub 2011 Sep 20.

9.
10.

α-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas.

Shen Y, Wang Z, Zhu J, Chen Y, Gu W, Liu Q.

Ann Diagn Pathol. 2014 Jun;18(3):146-50. doi: 10.1016/j.anndiagpath.2014.02.006. Epub 2014 Feb 25.

PMID:
24675392
11.

PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.

Chan ES, Alexander J, Swanson PE, Jain D, Yeh MM.

Am J Surg Pathol. 2012 May;36(5):737-43. doi: 10.1097/PAS.0b013e31824aba59.

PMID:
22498824
12.

PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study.

Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, Truong LD.

Mod Pathol. 2011 Jun;24(6):751-64. doi: 10.1038/modpathol.2011.3. Epub 2011 Feb 11.

13.

Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10.

Notohara K, Hamazaki S, Tsukayama C, Nakamoto S, Kawabata K, Mizobuchi K, Sakamoto K, Okada S.

Am J Surg Pathol. 2000 Oct;24(10):1361-71.

PMID:
11023097
14.

Paranuclear dot-like immunostaining for CD99: a unique staining pattern for diagnosing solid-pseudopapillary neoplasm of the pancreas.

Guo Y, Yuan F, Deng H, Wang HF, Jin XL, Xiao JC.

Am J Surg Pathol. 2011 Jun;35(6):799-806. doi: 10.1097/PAS.0b013e318219c036.

PMID:
21566515
15.

Immunophenotypic and prognostic analysis of PAX8 and TTF-1 expressions in neuroendocrine carcinomas of thymic origin: A comparative study with their pulmonary counterparts.

Bi Y, Deng Y, Li S, Zhou X, Chen Y, Ma D, Mao X, Guan Y, Chen J, Meng Y.

J Surg Oncol. 2016 Nov;114(6):697-702. doi: 10.1002/jso.24393. Epub 2016 Oct 20.

PMID:
27761900
16.

The Diagnostic Utility of PAX8 for Neuroendocrine Tumors: An Immunohistochemical Reappraisal.

Liau JY, Tsai JH, Jeng YM, Kuo KT, Huang HY, Liang CW, Yang CY.

Appl Immunohistochem Mol Morphol. 2016 Jan;24(1):57-63. doi: 10.1097/PAI.0000000000000149.

PMID:
25710581
17.

A comprehensive analysis of PAX8 expression in human epithelial tumors.

Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS.

Am J Surg Pathol. 2011 Jun;35(6):816-26. doi: 10.1097/PAS.0b013e318216c112.

PMID:
21552115
18.

Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms.

Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R.

Mod Pathol. 2008 Feb;21(2):192-200. Epub 2007 Dec 14.

19.

Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.

Yoxtheimer LM, Heymann JJ, Cohen C, Rao RA, Goyal A, Siddiqui MT.

Diagn Cytopathol. 2018 Dec;46(12):1010-1014. doi: 10.1002/dc.24088. Epub 2018 Oct 3.

PMID:
30284410
20.

Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.

Milione M, Maisonneuve P, Pellegrinelli A, Pusceddu S, Centonze G, Dominoni F, Brambilla C, Rubino M, Faggiano A, Buzzoni R, Concas L, Giacomelli L, Coppa J, Mazzaferro V, de Braud F.

Endocrine. 2017 Sep;57(3):512-517. doi: 10.1007/s12020-016-1180-6. Epub 2016 Nov 30.

PMID:
27905048

Supplemental Content

Support Center